SCHEMBL23851985

SCHEMBL23851985

N#Cc1c(C(F)(F)F)cc(-c2cnc(N)nc2)nc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.42
▸ ALDH1A1 P00352 6/20 0.42
▸ HPGD P15428 6/20 0.42
▸ L3MBTL1 Q9Y468 4/20 0.42
▸ GAA P10253 3/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ POLB P06746 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ PIK3CA P42336 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PIK3CD O00329 1/20 0.39
▸ NPSR1 Q6W5P4 3/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.37
▸ LMNA P02545 2/20 0.37
▸ KHK P50053 1/20 0.36
▸ GLA P06280 2/20 0.36
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ CRHBP P24387 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1919293 0.79 MAPT (0.60) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL1919926 0.78 KDM4E (0.57) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL5809565 0.78 KDM4E (0.50) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL23860762 0.76 BACE1 (0.40) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL1919396 0.76 KDM4E (0.55) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL29659097 0.73 L3MBTL1 (0.54) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL14967240 0.73 L3MBTL1 (0.54) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL1624009 0.73 KDM4E (0.40) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL29409508 0.73 KDM4E (0.40) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL22770667 0.72 POLB (0.45) KDM4EALDH1A1HPGDL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3883577-B1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY UNIV CASE WESTERN RESERVE (US) 2026-04-08 — — EP disclosed
US-12336982-B2 Compositions and methods of modulating short-chain dehydrogenase activity RODEO THERAPEUTICS CORPORATION (US) 2025-06-24 — — US disclosed
CN-113507931-B Compositions and methods for modulating short-chain dehydrogenase activity 卡斯西部储备大学 2025-05-27 — — CN disclosed
US-20250161277-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-05-22 — — US disclosed
US-20230039604-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY RODEO THERAPEUTICS CORPORATION 2023-02-09 — — US disclosed
US-20230039604-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY RODEO THERAPEUTICS CORPORATION 2023-02-09 — — US disclosed
EP-3883577-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2021-09-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161277-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS KDM4E 3506/4885ALDH1A1 126/4885HPGD 1/4885
US-12336982-B2 Compositions and methods of modulating short-chain dehydrogenase activity HPGD, GCDH, HPGDS KDM4E 3506/4885ALDH1A1 126/4885HPGD 1/4885
US-20230039604-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS KDM4E 3506/4885ALDH1A1 126/4885HPGD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback